Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Hin-Fung Yuen; Ka Kui Chan; Claire Grills; James T. Murray; Angela Platt-Higgins; Osama Sharaf Eldin; Ken O'Byrne; Pasi Janne; Dean A. Fennell; Patrick G. Johnston; Philip S. Rudland; Mohamed El-Tanani

doi:10.1158/1078-0432.CCR-11-2035

Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Hin-Fung Yuen, Ka Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Ken O'Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, Mohamed El-Tanani

Research output: Contribution to journal › Article › peer-review

77 Citations (Scopus)

Abstract

Purpose: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We nowinvestigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities.

Original language	English
Pages (from-to)	380-391
Number of pages	12
Journal	Clinical Cancer Research
Volume	18
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-11-2035
Publication status	Published - 15 Jan 2012

ASJC Scopus subject areas

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-11-2035

Cite this

Yuen, H.-F., Chan, K. K., Grills, C., Murray, J. T., Platt-Higgins, A., Eldin, O. S., O'Byrne, K., Janne, P., Fennell, D. A., Johnston, P. G., Rudland, P. S., & El-Tanani, M. (2012). Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways. Clinical Cancer Research, 18(2), 380-391. https://doi.org/10.1158/1078-0432.CCR-11-2035

@article{51edc1963a534266bdd8f0dd8302d319,

title = "Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways",

abstract = "Purpose: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We nowinvestigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities.",

author = "Hin-Fung Yuen and Chan, {Ka Kui} and Claire Grills and Murray, {James T.} and Angela Platt-Higgins and Eldin, {Osama Sharaf} and Ken O'Byrne and Pasi Janne and Fennell, {Dean A.} and Johnston, {Patrick G.} and Rudland, {Philip S.} and Mohamed El-Tanani",

year = "2012",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-11-2035",

language = "English",

volume = "18",

pages = "380--391",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

Yuen, H-F, Chan, KK, Grills, C, Murray, JT, Platt-Higgins, A, Eldin, OS, O'Byrne, K, Janne, P, Fennell, DA, Johnston, PG, Rudland, PS & El-Tanani, M 2012, 'Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways', Clinical Cancer Research, vol. 18, no. 2, pp. 380-391. https://doi.org/10.1158/1078-0432.CCR-11-2035

TY - JOUR

T1 - Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

AU - Yuen, Hin-Fung

AU - Chan, Ka Kui

AU - Grills, Claire

AU - Murray, James T.

AU - Platt-Higgins, Angela

AU - Eldin, Osama Sharaf

AU - O'Byrne, Ken

AU - Janne, Pasi

AU - Fennell, Dean A.

AU - Johnston, Patrick G.

AU - Rudland, Philip S.

AU - El-Tanani, Mohamed

PY - 2012/1/15

Y1 - 2012/1/15

N2 - Purpose: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We nowinvestigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities.

AB - Purpose: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We nowinvestigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities.

U2 - 10.1158/1078-0432.CCR-11-2035

DO - 10.1158/1078-0432.CCR-11-2035

M3 - Article

SN - 1078-0432

VL - 18

SP - 380

EP - 391

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this